tradingkey.logo

Seres Therapeutics Inc <MCRB.OQ> expected to post a loss of 20 cents a share - Earnings Preview

ReutersMar 5, 2025 1:33 PM
  • Seres Therapeutics Inc MCRB.OQ MCRB.O is expected to show a fall in quarterly revenue when it reports results on March 13 for the period ending December 31 2024

  • ​LSEG's mean analyst estimate for Seres Therapeutics Inc is for a loss of 20 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and 2 "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Seres Therapeutics Inc is $1.25​, above​ its last closing price of $0.67. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.24

-0.25

-0.38

Missed

-54.8

Jun. 30 2024

-0.27

-0.27

-0.22

Beat

19.7

Mar. 31 2024

-0.35

-0.34

-0.27

Beat

20.8​

Dec. 31 2023

-0.40

-0.50

-0.32

Beat

35.6

​​Sep. 30 2023

-0.49

-0.50

-0.37

Beat

26.2

Jun. 30 2023

0.53

0.53

0.36

Missed

-32.6​

Mar. 31 2023

-0.56

-0.55

-0.57

Missed

-3.8

Dec. 31 2022

-0.30

-0.46

-0.54

Missed

-16.1

This summary was machine generated March 5 at 13:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI